UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of July 2026

Commission File Number: 001-42834

Regentis Biomaterials Ltd.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, Herzliya, ~~Israel~~ 4676652

Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On July 29, 2026, the Adjourned Annual General Meeting of Shareholders of Regentis Biomaterials Ltd. (the “Company”) ~~convened~~approved each anof ~~Annual~~the ~~General~~fourteen ~~Meeting~~proposals ofbrought ~~Shareholders~~before (the ~~“Annual General~~Company’s ~~Meeting”).~~shareholders ~~However,~~at the ~~Annual~~meeting, ~~General~~in ~~Meeting~~accordance ~~was~~with ~~adjourned~~the majority required for ~~one~~each ~~week~~proposal. toEach ~~the~~of ~~same~~those ~~day,~~proposals ~~time~~was ~~and~~described ~~place~~in ~~due~~the toCompany’s ~~lack~~Notice ~~of quorum.~~and ~~Accordingly,~~Proxy Statement with respect to the Company’s Annual General Meeting ~~will~~of beShareholders, ~~reconvened~~dated onMay ~~Tuesday~~28, ~~July 9~~2026, ~~2026~~attached atas ~~3:00~~Exhibit p99.~~m.,~~1 ~~Israel~~to ~~time,~~the atCompany’s ~~the~~Form ~~offices~~6-K that was furnished ofto the ~~Company’s~~U.S. ~~attorneys,~~Securities ~~Amit~~and Exchange Commission on May 28, ~~Pollak~~2026, ~~Matalon~~as &amended Coby the Amended Notice and Proxy Statement attached as Exhibit 99.,1 atto ~~APM~~the ~~House,~~Company’s 18Form ~~Raoul~~6-K/A ~~Wallenberg~~that Stwas furnished to the U.,S. ~~Building~~Securities D,and ~~6th~~Exchange ~~floor,~~Commission ~~Ramat Hachayal,~~on ~~Tel~~June ~~Aviv~~4, ~~Israel~~2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: July 2, 2026	/s/ Ehud Geller
Date: July 9, 2026	/s/ Ehud Geller
	Ehud Geller Chairman and Chief Executive Officer
	Ehud Geller
	Chairman and Chief Executive Officer

Filing Compare · REGENTIS BIOMATERIALS LTD.